These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32314853)

  • 1. Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England.
    Bakhai A; Petri H; Vahidnia F; Wolf C; Ding Y; Foskett N; Sculpher M
    J Eval Clin Pract; 2021 Feb; 27(1):119-133. PubMed ID: 32314853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study.
    Ahn HJ; Lee SR; Choi J; Lee KY; Kwon S; Choi EK; Oh S; Lip GYH
    Europace; 2024 Feb; 26(2):. PubMed ID: 38290433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
    Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
    BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study.
    Kezerle L; Tsadok MA; Berliner Senderey A; Hoshen M; Leventer-Roberts M; Reges O; Leibowitz M; Haim M
    J Cardiovasc Electrophysiol; 2020 Jun; 31(6):1356-1363. PubMed ID: 32212197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
    Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
    BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    van den Dries CJ; Pajouheshnia R; van den Ham HA; Souverein P; Moons KGM; Hoes AW; Geersing GJ; van Doorn S
    Br J Clin Pharmacol; 2023 Feb; 89(2):751-761. PubMed ID: 36102068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients.
    Tedla YG; Schwartz SM; Silberman P; Greenland P; Passman RS
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104718. PubMed ID: 32122777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Lip GYH; Chen SA
    Circulation; 2018 Jul; 138(1):37-47. PubMed ID: 29490992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients.
    Ogilvie IM; Welner SA; Cowell W; Lip GY
    Thromb Haemost; 2011 Jul; 106(1):34-44. PubMed ID: 21614409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.